Pfizer on Tuesday said it expected 2021 sales of the COVID-19 vaccine it developed with German partner BioNTech SE to reach US$36 billion and forecast another US$29 billion from the shot in 2022, topping analyst estimates for both years. The US pharmaceutical company said it is seeking to sign more vaccine deals with countries, which could drive sales even higher next year. It has the capacity to produce 4 billion doses in 2022 and has based its projections on...